Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210404 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
A Phase 1 study of Chronic Hepatitis C, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT01210404: Completed Phase 1 study of Chronic Hepatitis C, sponsored by Pfizer.
NCT01210404 is a Phase 1 study of Chronic Hepatitis C that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01210404, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
Conditions Studied
Interventions
- DRUG filibuvir
Study Locations (2)
Kansas
- Pfizer Investigational Site - Overland Park
- Pfizer Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT01210404 record still lists
NCT01210404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which filibuvir is the first listed.
NCT01210404 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01210404 about?
NCT01210404 is a clinical study titled "Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance". Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
What is the current status of trial NCT01210404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-02. Estimated completion is 2011-06.
What conditions does trial NCT01210404 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01210404?
The interventions under investigation include: filibuvir (DRUG).
Who is sponsoring clinical trial NCT01210404?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01210404 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01210404's enrollment target sits among peer trials
12 16th of 16 the lowest of 16 other Chronic Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
COMPLETED · Phase 1
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
COMPLETED · Phase 1
-
Q-Trial in Patients With Hepatitis C
COMPLETED · Phase 1
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia